Merck & Co Option Alert: Jun, 2026 $80 Calls at the Bid: 750 vs 1859 OI; Earnings 7/29 Before Open 

Merck & Co Option Alert: Jun, 2026 $80 Calls at the Bid: 750 @ $10.55 vs 1859 OI; Earnings 7/29 Before Open Ref=$82.365

Merck & Co (NYSE:MRK) Bolsa

MERCK & CO. INC.

Merck & Co

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

wall street ai3

Large Cap

Education

AAPL

AMZN

CSCO

SPDR Dow Jones Industrial Average ETF Trust

MSFT

NVDA

IBM, Goldman Sachs y JPMorgan lideran el Dow Jones en 2025, mientras Apple y UnitedHealth registran fuertes caídas.

Estas son las mejores y peores acciones del Dow Jones en la primera mitad de 2025

Medical,Billing,Document,And,Dollar,Banknote,,Calculator,,Stathoscope.,Medical,Treatment

Health Care

Markets

AMGN

REGN

RHHBY

Trump anuncia una orden ejecutiva para reducir precios de medicamentos hasta un 80 %, aplicando la política de &#34;Nación Más Favorecida&#34;.

Trump firma orden ejecutiva histórica para reducir precios de medicamentos en EE. UU.

Eli Lilly and Co.

Equities

Government

News

ABBV

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Trump quiere que las farmacéuticas vuelvan a EE. UU. ¿Cómo afectarán sus aranceles a las acciones del sector?

Trump presiona a farmacéuticas con aranceles para forzar regreso a EE. UU.

Merck & Co Inc

Marker Therapeutics Inc

MARKY CORP by MARKY CORP.

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WAY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$40.00</td>
<td>$321.0K</td>
<td>257</td>
<td>3.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$157.50</td>
<td>$36.0K</td>
<td>5.3K</td>
<td>2.8K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$60.00</td>
<td>$25.0K</td>
<td>746</td>
<td>1.7K</td>
</tr>
<tr>
<td>PGEN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1.50</td>
<td>$35.0K</td>
<td>1.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>SMLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$45.00</td>
<td>$149.9K</td>
<td>270</td>
<td>864</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/01/25</td>
<td>$83.00</td>
<td>$25.0K</td>
<td>182</td>
<td>817</td>
</tr>
<tr>
<td>JAZZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$110.00</td>
<td>$165.3K</td>
<td>20</td>
<td>205</td>
</tr>
<tr>
<td>SMMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$10.00</td>
<td>$36.0K</td>
<td>208</td>
<td>177</td>
</tr>
<tr>
<td>HROW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$28.00</td>
<td>$62.5K</td>
<td>114</td>
<td>100</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$260.00</td>
<td>$37.5K</td>
<td>2.7K</td>
<td>62</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For WAY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAY#NASDAQ">WAY</a>), we notice a call option trade that happens to be bullish, expiring in 30 day(s) on August 15, 2025. This event was a transfer of 2293 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $321.0K, with a price of $140.0 per contract. There were 257 open contracts at this strike prior to today, and today 3002 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a call option trade with bullish sentiment. It expires in 2 day(s) on July 18, 2025. Parties traded 50 contract(s) at a $157.50 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $720.0 per contract. There were 5363 open contracts at this strike prior to today, and today 2820 contract(s) were bought and sold. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a call option trade with bearish sentiment. It expires in 9 day(s) on July 25, 2025. Parties traded 100 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $251.0 per contract. There were 746 open contracts at this strike prior to today, and today 1703 contract(s) were bought and sold. 
• Regarding PGEN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>), we observe a put option sweep with bearish sentiment. It expires in 93 day(s) on October 17, 2025. Parties traded 1000 contract(s) at a $1.50 strike. This particular put needed to be split into 32 different trades to become filled. The total cost received by the writing party (or parties) was $35.0K, with a price of $35.0 per contract. There were 1470 open contracts at this strike prior to today, and today 1020 contract(s) were bought and sold. 
• Regarding SMLR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), we observe a call option trade with neutral sentiment. It expires in 156 day(s) on December 19, 2025. Parties traded 147 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $149.9K, with a price of $1020.0 per contract. There were 270 open contracts at this strike prior to today, and today 864 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on August 1, 2025. Parties traded 99 contract(s) at a $83.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $253.0 per contract. There were 182 open contracts at this strike prior to today, and today 817 contract(s) were bought and sold. 
• Regarding JAZZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), we observe a put option sweep with bullish sentiment. It expires in 93 day(s) on October 17, 2025. Parties traded 190 contract(s) at a $110.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $165.3K, with a price of $870.0 per contract. There were 20 open contracts at this strike prior to today, and today 205 contract(s) were bought and sold. 
• For SMMT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>), we notice a call option trade that happens to be bullish, expiring in 184 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $1800.0 per contract. There were 208 open contracts at this strike prior to today, and today 177 contract(s) were bought and sold. 
• For HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we notice a call option trade that happens to be bearish, expiring in 2 day(s) on July 18, 2025. This event was a transfer of 100 contract(s) at a $28.00 strike. The total cost received by the writing party (or parties) was $62.5K, with a price of $625.0 per contract. There were 114 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be bullish, expiring in 184 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $260.00 strike. The total cost received by the writing party (or parties) was $37.5K, with a price of $1875.0 per contract. There were 2768 open contracts at this strike prior to today, and today 62 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

HROW

JAZZ

PGEN

SMLR

SMMT

10 Health Care Stocks Whale Activity In Today's Session

<a href="https://asia.nikkei.com/Business/Pharmaceuticals/Japan-discards-2.5m-doses-of-expired-COVID-drugs-from-Pfizer-Merck">https://asia.nikkei.com/Business/Pharmaceuticals/Japan-discards-2.5m-doses-of-expired-COVID-drugs-from-Pfizer-Merck</a>

General

'Japan discards 2.5m doses of expired COVID drugs from Pfizer, Merck'- Nikkei Asia

On Monday, the U.S. Food and Drug Administration (FDA) agreed to review GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">who are at increased risk</a>.
GSK's RSV vaccine is approved in the U.S. to prevent lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, as well as those aged 50-59 years at increased risk for LRTD caused by RSV.
RSV, a common contagious virus affecting the lungs and breathing passages, impacts an estimated 64 million people of all ages globally every year. More than 125 million adults in the U.S. are under 50. An estimated 21 million of these people have at least one diagnosed risk factor for severe RSV infection, such as chronic obstructive pulmonary disease, asthma, congestive heart failure, and coronary heart disease.
The regulatory submission is <a href="https://us.gsk.com/en-us/media/press-releases/fda-accepts-application-to-review-expanded-use-of-gsk-s-rsv-vaccine-arexvy/" target="_blank" rel="noreferrer noopener">supported</a> by a Phase 3b trial evaluating immune response and safety in adults aged 18-49 who are at increased risk compared to adults aged 60 and above.
The safety and reactogenicity data were consistent with those from the Phase 3 program, which supported the vaccine&#8217;s initial approval in the U.S.
A regulatory decision by the FDA on this submission is expected in the first half of 2026.
In June, the FDA expanded approval of Moderna Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) respiratory syncytial virus vaccine to adults aged 18-59 at increased risk <a href="https://www.benzinga.com/news/health-care/25/06/45921359/fda-expands-modernas-rsv-vaccine-use-to-at-risk-adults-aged-18-59-amid-cdc-panel-shake-up" target="_blank" rel="noreferrer noopener">for disease</a>. That same month, the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Enflonsia (clesrovimab-cfor) as an option for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants younger than 8 months of age who are born during or entering their first RSV season.
With a <a target="_blank" href="https://www.cdc.gov/media/releases/2025/2025-cdcs-advisory-committee-on-immunization-concludes-meeting-with-joint-statement.html" rel="noreferrer noopener">five-to-two </a>majority, RFK Jr.'s newly constituted committee made its first ruling. This body was formed after RFK Jr. entirely replaced the previous 17-member panel <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46136734/rfk-jrs-cdc-panel-recommends-mercks-rsv-shot-for-infants" rel="noreferrer noopener">with his selections</a>.
Also, in June, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced that it will begin shipping Beyfortus (nirsevimab) in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and <a href="https://www.benzinga.com/news/health-care/25/06/45839621/beyfortus-output-tripled-as-sanofi-astrazeneca-scale-up-for-rsv-season" target="_blank" rel="noreferrer noopener">runs through March</a>.
In collaboration with its partner AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Sanofi has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.
Last week, GSK announced it has started shipping doses of its trivalent seasonal influenza vaccines to U.S. healthcare providers and pharmacies in preparation for the 2025-26 flu season.
This immediately follows FDA licensing and approval of the lot release. FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people <a href="https://www.benzinga.com/pressreleases/25/07/b46342250/gsk-begins-shipping-influenza-vaccine-doses-for-the-2025-26-flu-season" target="_blank" rel="noreferrer noopener">six months and older</a>.
Price Action: GSK stock is down 1.36% at $37.77 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46410829/analyst-with-sell-rating-on-aapl-stock-warns-tim-cooks-company-is-unprepared-for-something-that-transformational" target="_blank" rel="noreferrer noopener">Analyst With Sell Rating On AAPL Stock Warns Tim Cook&#8217;s Company &#8216;Is Unprepared For Something That Transformational&#8217;</a></li>
</ul>
Photo: Shutterstock

MRNA

GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults

Deep-pocketed investors have adopted a bearish approach towards Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRK usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Merck &amp; Co. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 12% leaning bullish and 75% bearish. Among these notable options, 3 are puts, totaling $179,100, and 5 are calls, amounting to $323,698.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $75.0 to $115.0 for Merck &amp; Co during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Merck &amp; Co's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Merck &amp; Co's significant trades, within a strike price range of $75.0 to $115.0, over the past month.
<h3>Merck &amp; Co Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752591644_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$0.82</td>
<td>$0.81</td>
<td>$0.82</td>
<td>$90.00</td>
<td>$163.2K</td>
<td>16.9K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$32.3</td>
<td>$31.75</td>
<td>$32.3</td>
<td>$115.00</td>
<td>$77.5K</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$31.7</td>
<td>$31.35</td>
<td>$31.7</td>
<td>$115.00</td>
<td>$76.0K</td>
<td>0</td>
<td>24</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$13.85</td>
<td>$13.65</td>
<td>$13.72</td>
<td>$75.00</td>
<td>$67.2K</td>
<td>617</td>
<td>49</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/18/26</td>
<td>$11.55</td>
<td>$11.5</td>
<td>$11.55</td>
<td>$80.00</td>
<td>$34.6K</td>
<td>48</td>
<td>33</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
In light of the recent options history for Merck &amp; Co, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Merck &amp; Co</h3>
<ul>
<li>With a volume of 1,772,033, the price of MRK is down -1.7% at $82.25. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 14 days.</li>
</ul>
<h3>What Analysts Are Saying About Merck &amp; Co</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $98.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Merck &amp; Co, maintaining a target price of $98. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Merck &amp; Co with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Merck & Co Unusual Options Activity For July 15

A report on July 14, 2025 shows that Representative Julie Johnson from Texas purchase stock in 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>), valued between $2,002 and $30,000. According to the July filing, the transaction occurred on June 18, 2025.
At the time of writing, 3M shares are trading down 0.02% at $157.88.
<h3>What Representative Has Been Trading Recently</h3>
Over the past three years, Julie Johnson executed 271 trades totaling over $369 thousand. The largest of these trades were in Tesla and Amazon.com stock. Some of the key transactions the Rep. has executed recently include: 
<ul>
<li>Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>): $1,001 - $15,000 Sale</li>
<li>3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>): $1,001 - $15,000 Purchase</li>
<li>Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): $1,001 - $15,000 Purchase</li>
</ul>
Here is a list of Julie Johnson's most recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palantir Technologies</td>
<td>PLTR</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-06-30</td>
</tr>
<tr>
<td>3M</td>
<td>MMM</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-06-18</td>
</tr>
<tr>
<td>Merck &amp; Co</td>
<td>MRK</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-06-13</td>
</tr>
<tr>
<td>Capital One Finl</td>
<td>COF</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>E</td>
<td>2025-05-19</td>
</tr>
<tr>
<td>Fidelity National Info</td>
<td>FIS</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-05-15</td>
</tr>
</tbody>
</table>
To stay updated on Julie Johnson's trades and other congressional trades, try our <a href="https://www.benzinga.com/gov-trades/members/julie-johnson">government trades tool</a> for live updates!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>The Importance of Congressional Transactions</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Politics

Trading Ideas

PLTR

This House of Representative Just Bought Up To $30K In 3M Stock

Bristol-Myers Squibb &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) is gearing up to announce its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45900314/bristol-myers-squibb-to-report-results-for-second-quarter-2025-on-july-31-2025" rel="noreferrer noopener">second-quarter 2025</a> earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
While revenue and underlying earnings per share estimates for the current quarter and full-year 2025 have seen slight downward revisions, the U.S. pharma giant anticipates a low-single-digit percentage increase in total revenue for the later 2020s, primarily driven by updated assumptions for its cancer drug Yervoy.
The upcoming earnings call is expected to shed light on the performance of key products, future milestones, and the impact of U.S. drug pricing policies on the broader industry.
Read Next: <a target="_blank" href="https://www.benzinga.com/news/legal/25/06/46098969/bristol-myers-faces-scrutiny-for-allegedly-rigging-market-on-2b-cancer-drug" rel="noreferrer noopener">Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2 Billion Cancer Drug</a>
Bank of America Securities (BofA) updated the company&#8217;s earnings model. For the second quarter, BofA&#8217;s total revenue estimates and EPS decline by more than 1%, with no significant changes; for 2025, there are no major changes, revenue and underlying earnings per share decrease by more than 1%.
For the later 2020s, total revenue estimates increase by a low-single-digit percentage, primarily related to updated loss-of-exclusivity assumptions for Yervoy. BofA maintains a Neutral rating <a target="_blank" href="https://www.benzinga.com/quote/BMY/analyst-ratings" rel="noreferrer noopener">and a price forecast of $56</a>, using an 8x P/E multiple on updated 2025E EPS.
Analyst Tim Anderson notes that while Bristol-Myers Squibb has described the Inflation Reduction Act&#8217;s (IRA) Medicare Part D reform as &#8220;potentially net neutral across the portfolio,&#8221; certain products like Pomalyst, Revlimid, Camzyos, and Orencia (subcutaneous) are expected to have greater headwinds.
As the upcoming earnings call approaches, investors and analysts will be keenly focused on a few critical areas that will shape Bristol Myers Squibb&#8217;s narrative.
A significant portion of the discussion is anticipated to revolve around the evolving landscape of U.S. drug pricing policies. The specter of initiatives like the &#8216;most favored nation&#8217; rule, alongside the potential imposition of pharma-specific tariffs under Section 232, casts a long shadow over the entire pharmaceutical industry, and Bristol Myers Squibb is certainly not immune to these systemic pressures.
Beyond these broader industry concerns, the call will undoubtedly provide crucial updates on the commercial performance and future potential of key products within the company&#8217;s portfolio, including Cobenfy, Camzyos, Reblozyl, and Breyanzi.
Their trajectory in the market will be a strong indicator of the company&#8217;s immediate revenue streams. Additionally, stakeholders will be eager to hear about upcoming milestones slated for 2025, which could provide insights into future product launches, regulatory decisions, or significant clinical trial readouts.
While the company navigates these operational and policy challenges, its valuation remains a talking point among analysts. As analyst Anderson points out, Bristol Myers Squibb &#8220;remains one of the cheaper companies in large-cap biopharma,&#8221; but it&#8217;s no longer unusually cheap. Its price-to-earnings ratio of 7 to 8 times expected 2025 earnings is now similar to peers like Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), and Merck &amp; Co. Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>).
Despite this current valuation, the road ahead appears challenging. The company is bracing for several tough years, with an anticipated decline in earnings primarily driven by the relentless pressure from generic competition.
This looming threat to its established revenue streams means that achieving meaningful medium-term growth will be a significant hurdle for Bristol Myers Squibb to overcome.
Price Action: BMY stock is trading higher by 1.52% to $47.57 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46396595/jpmorgan-citi-to-kick-off-bank-earnings-as-wall-street-sees-profit-boom" target="_blank" rel="noreferrer noopener">JPMorgan, Citi To Kick Off Bank Earnings As Wall Street Sees Profit Boom</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Price Target

Reiteration

Analyst Ratings

BIIB

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an investigational once-monthly, oral nucleoside reverse transcriptase translocation inhibitor (NRTTI) for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 (MK-8527-011, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07044297&amp;esheet=54289681&amp;newsitemid=20250714554719&amp;lan=en-US&amp;anchor=NCT+07044297&amp;index=1&amp;md5=6b7d364318c150881c75b2c4be810ba6">NCT 07044297</a>) trial will evaluate the safety and efficacy of MK-8527 among people with greater likelihood of HIV-1 exposure in 16 countries and will begin enrolling in August 2025. In collaboration with the Gates Foundation, the EXPrESSIVE-10 (MK-8527-010) trial will evaluate the safety and efficacy of MK-8527 in women and adolescent girls in sub-Saharan Africa and will begin enrolling in the next few months.

Global

Merck, In Collaboration With The Gates Foundation, Launches Global Phase 3 Trials For Monthly Oral HIV PrEP MK-8527, Targeting High-Risk Populations In 16 Countries And Sub-Saharan Africa

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Monday released topline data from the BaxHTN Phase 3 trial of baxdrostat in patients with uncontrolled or treatment-resistant hypertension.
The trial included patients who were treated with two different antihypertensive medications and patients with resistant hypertension being treated with three or more different antihypertensive medications, one of which is a diuretic.
The <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-met-primary-and-all-secondary-endpts-in-baxhtn-phiii-trial.html" rel="noreferrer noopener">trial</a> showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/contracts/25/07/46249640/astrazeneca-in-15b-talks-for-drug-that-could-upend-lung-cancer-treatment" rel="noreferrer noopener">AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment</a>
The trial also met all secondary endpoints. Patients with uncontrolled or treatment-resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated and had a favourable safety profile.
There are 1.3 billion people worldwide living with hypertension. When uncontrolled, hypertension can lead to a higher risk of heart attack, stroke, heart failure, and kidney disease. In the U.S., approximately 50% of hypertensive patients who are on multiple treatments do not have their blood pressure under control.
The data will be shared with regulatory authorities worldwide and presented in a late‑breaking Hot Line session at the European Society of Cardiology (ESC) Congress&nbsp;in August 2025.
AstraZeneca acquired baxdrostat by purchasing CinCor Pharma, Inc. in February 2023. A contingent value right of $10 per share in cash ($0.5 billion) is payable to former CinCor shareholders upon submitting a new drug application in the U.S. or Europe.
In related news, Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) recently received priority review from the U.S. Food and Drug Administration (FDA) for its supplemental Biologics License Application (sBLA) for <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46230333/mercks-hypertension-drug-on-fda-fast-track-for-label-expansion" rel="noreferrer noopener">Winrevair (sotatercept-csrk)</a>.
This application aims to update the U.S. product label based on compelling data from the Phase 3 ZENITH trial. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of October 25, 2025.
In 2024, Winrevair was approved for adults with pulmonary arterial hypertension (PAH, Group 1 PH) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.
Price Action: AZN stock is trading higher by 0.60% to $71.57 during the premarket session at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46387027/alibaba-bleeds-billions-as-delivery-price-war-erases-100-billion-in-market-value" target="_blank" rel="noreferrer noopener">Alibaba Bleeds Billions As Delivery Price War Erases $100 Billion In Market Value</a></li>
</ul>
Photo by Piotr Swat Shutterstock

AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to &#8220;benefit&#8221; from the levies. 
What Happened: Trump announced on Tuesday that the pharma tariffs, part of a Section 232 investigation launched in April, are expected to be detailed by month's end, with a grace period of "about a year, year and a half" before implementation.
Barclays cautioned that a 200% tariff would "inflate production costs, compress profit margins, and risk supply chain disruptions.&#8221; However, the delay offers little relief, <a href="https://www.cnbc.com/2025/07/11/trump-200percent-pharma-tariffs-threaten-to-push-up-drug-prices-hit-margins.html">as</a> CNBC reported, quoting UBS analysts that it's "insufficient time" for firms to relocate manufacturing, typically a four-to-five-year process. 
But despite the potential negative impact on pharma companies, Louis Navellier told <a href="https://www.benzinga.com">Benzinga </a>that Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is &#8220;expected to benefit from tariffs on pharmaceutical imports, since the company has been boosting its domestic manufacturing.&#8221;
Additionally, Thomas Shipp, head of equity research at LPL Financial, told <a href="https://pro.benzinga.com/dashboard">Benzinga</a> that Lilly's attempt to try &#8220;to avoid PBMs,&#8221; exemplified by its direct-to-consumer model, &#8216;LillyDirect&#8217; in partnership with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), positions it to bypass traditional pharmacy benefit managers, enhancing its resilience against tariff-related disruptions.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46361386/bitcoin-breaches-118k-but-these-btc-mining-firms-are-still-priced-like-its-at-58k-heres-how-these-mining-stocks-could-explode">Bitcoin Breaches $118K, But These BTC Mining Firms Are Still Priced Like It&#8217;s At $58K: Here&#8217;s How These Mining Stocks Could Explode</a>
Why It Matters: Additionally, Lilly's strategic moves, including a $1.3 billion <a href="https://www.benzinga.com/m-a/25/06/45970361/eli-lilly-expands-into-gene-editing-with-verve-therapeutics-acquisition">acquisition of Verve Therapeutics</a>, signal its focus on innovation and U.S.-based growth. 
Ark Research noted that this acquisition validates gene-editing therapies for cardiovascular disease, a market with "trillions of dollars" in potential, as Lilly scales solutions like PCSK9-targeting therapies that reduce LDL-C by up to 69%.
Apart from the effects on the profitability of pharmaceutical companies, according to PhRMA, the tariffs could raise U.S. drug prices by $51 billion annually with just a 25% tariff levy, potentially increasing costs by 12.9%.
Price Action: Eli Lilly stock declined 0.078% in premarket on Friday; it was up 1.62% on a year-to-date basis but down by 15.36% over the last year.
Benzinga Edge Stock Rankings shows that LLY had a weak momentum and value ranking; however, its growth and quality metrics were very strong. The details of all the important indicators are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="163" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png" alt="" class="wp-image-981662" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-300x48.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-768x122.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge.png 1039w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
These are some pharma stocks and ETFs that could be impacted as Trump warned on Tuesday that long-awaited industry-wide tariffs would be announced "very soon".
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>1.62%</td>
<td>-15.36%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>8.67%</td>
<td>14.77%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-14.56%</td>
<td>19.07%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-21.73%</td>
<td>-48.18%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.12%</td>
<td>-10.05%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>24.66%</td>
<td>63.70%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-15.28%</td>
<td>-34.85%</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>15.85%</td>
<td>-7.60%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>9.49%</td>
<td>5.34%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>3.50%</td>
<td>-3.73%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>3.15%</td>
<td>-0.88%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>0.68%</td>
<td>-0.49%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-0.16%</td>
<td>2.31%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>25.74%</td>
<td>30.34%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-1.00%</td>
<td>-4.29%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-14.12%</td>
<td>-14.74%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46336115/as-trump-calls-for-3-percentage-point-rate-cut-too-late-jerome-powell-to-resign-june-fed-minutes-sh">As Trump Calls For 3-Percentage Point Rate Cut, &#8216;Too Late&#8217; Jerome Powell To Resign, June Fed Minutes Show &#8216;Uncertainty&#8217; Reigns Supreme</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shuttertsock

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

12-Month Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO&#xAE; QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly1 injectable product to treat and protect dogs from fleas and ticks. The product is expected to be available at veterinary clinics and hospitals nationwide by August 2025.
BRAVECTO QUANTUM was first approved in Australia and New Zealand in 2023, followed by the European Union (EU) in 2024 and now the U.S. in 2025. In total, BRAVECTO QUANTUM is currently approved in more than 50 countries worldwide.

Merck Animal Health Gains FDA Approval For BRAVECTO QUANTUM, First Once-Yearly Injectable Flea And Tick Treatment For Dogs, U.S. Launch Set For August 2025

Live On CNBC, Kevin Simpson Announces Bought More Merck

Morgan Stanley analyst Terence Flynn maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Equal-Weight and lowers the price target from $99 to $98.

Morgan Stanley Maintains Equal-Weight on Merck & Co, Lowers Price Target to $98

Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for doravirine/islatravir (DOR/ISL), an investigational, once-daily, oral, two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The FDA has set a target action date of April 28, 2026, for the application under the Prescription Drug User Fee Act (PDUFA).
"Merck has been at the forefront of HIV research for more than 35 years and we are pleased to continue our work to innovate and deliver new options that aim to meet the needs of the HIV community," said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. "The health needs of people living with HIV often change over time – whether it's managing comorbidities or navigating complex medication regimens. We believe DOR/ISL, if approved, will represent an important new complete regimen option designed to help meet their diverse needs."
The NDA is based on findings at Week 48 of two pivotal Phase 3 clinical trials (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05631093%3Fterm%3Dislatravir%26page%3D2%26rank%3D20&amp;esheet=54288506&amp;newsitemid=20250710518672&amp;lan=en-US&amp;anchor=MK-8591A-051&amp;index=1&amp;md5=19f532bbd62d49517c24c6053c9e0533">MK-8591A-051</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05630755&amp;esheet=54288506&amp;newsitemid=20250710518672&amp;lan=en-US&amp;anchor=MK-8591A-052&amp;index=2&amp;md5=f8766e7f07603170fb6d72efa6249476">MK-8591A-052</a>) where DOR/ISL was demonstrated to be non-inferior to baseline antiretroviral therapy (bART) in the open-label trial MK-8591A-051 and non-inferior to bictegravir/emtrictabine/tenofovir alafenamidei [BIC/FTC/TAF (50mg/200mg/25mg)] in the double-blind trial MK-8591A-052. Across both trials, the safety profile of DOR/ISL was generally comparable to comparator baseline antiretroviral regimens in trial MK-8591A-051 and BIC/FTC/TAF in trial MK-8591A-052. Data from these trials <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fmerck-announces-positive-data-from-phase-3-trials-that-show-the-investigational-once-daily-oral-two-drug-regimen-of-doravirine-islatravir-dor-isl-maintained-hiv-1-viral-suppression-at-week-48%2F%23%3A%7E%3Atext%3DMarch%252012%252C%25202025%252012%3A26%2520pm%2520ET.%2520DOR%2FISL%2Cto%2520comparator%2520antiretroviral%2520therapies%2520in%2520adults%2520with&amp;esheet=54288506&amp;newsitemid=20250710518672&amp;lan=en-US&amp;anchor=were+presented&amp;index=3&amp;md5=3764ef6f22589fe8271e55c80e83d584">were presented</a> during the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

Regulations

Merck's New Once-Daily HIV Pill Moves Closer to FDA Approval With April 2026 Decision Date

Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) on Wednesday reported preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab), and standard chemotherapy after <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46316119/kazia-therapeutics-reports-early-efficacy-data-from-first-triple-negative-breast-cancer-patient-re" rel="noreferrer noopener">completing Cycle 1 (21 days) of dosing</a>.
The patient, a 61-year-old woman with metastatic <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">triple-negative breast cancer</a> localized to the left upper lobe of the lung, has shown highly encouraging preliminary results at 21 days, with a &gt;50% reduction in circulating tumor cells (CTCs) and a notable decrease in CTC clusters.
Read Next: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45889834/kazia-therapeutics-kzia-stock-surges-77-on-positive-preclinical-data-for-breast-cancer-drug" rel="noreferrer noopener">Kazia Therapeutics (KZIA) Stock Surges 77% On Positive Preclinical Data For Breast Cancer Drug</a>
The early data in this first patient closely mirror the mechanistic preclinical findings published in Molecular Cancer Therapeutics, which highlight that Paxalisib, when combined with immunotherapy, significantly disrupted both single CTCs and multicellular clusters in preclinical models.
<h2 class="wp-block-heading">Key Highlights</h2>
There has been a reduction of more than 50% in the total CTC count.
A similar decrease in circulating tumor cell (CTC) clusters is observed, and these aggregates are linked to an increased potential for metastasis.
Reduction in the&nbsp;mesenchymal phenotype of the remaining CTCs; this phenotype is one of the hallmarks of aggressive metastatic seeding cancer cells.&nbsp;
First-in-human data support the potential for potent&nbsp;CTC mobilization suppression by this combination.
<h2 class="wp-block-heading">Why It Matters</h2>
CTC clusters have long been recognized as critical mediators of metastasis and markers of poor prognosis. They are known to resist apoptosis, evade immune detection, and seed new tumor sites.
Some studies have shown standard chemotherapy to transiently increase CTC and cluster counts within the first cycle, with levels sometimes doubling before normalizing after cycle two.
In contrast, immunotherapy alone has demonstrated variable impact, often showing delayed or modest effects on CTCs, likely due to immune-mediated mechanisms over weeks to months.
<h2 class="wp-block-heading">What Are The Next Steps?</h2>
Explore the potential relationship between CTC kinetics and radiographic responses.
Enrollment continues in the Phase 1b study, expanding cohort size to assess safety, tolerability, and pharmacodynamics.
Planned a comprehensive analysis of the immune microenvironment and CTC kinetics across all patients through serial monitoring.
Longer-term follow-up will include imaging, progression-free survival, and assessment of correlation with molecular biomarkers.
Price Action: KZIA stock is up 22.9% at $8.39 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46319996/qualcomms-most-powerful-chip-yet-is-here-and-its-built-to-unlock-samsungs-galaxy-ai" target="_blank" rel="noreferrer noopener">Qualcomm&#8217;s Most Powerful Chip Yet Is Here—And It&#8217;s Built To Unlock Samsung&#8217;s Galaxy AI</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Movers

KZIA

Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps

Wall Street rose on Wednesday as investors shrugged off fresh trade uncertainty after the White House delayed the start of new tariffs to Aug. 1, raising hopes for <a href="https://www.benzinga.com/topic/tariffs">new rounds of negotiations.</a>
This came just a day after President Donald Trump floated sweeping tariffs, including a 50% tariff on copper and a potential 200% tariff on pharmaceuticals, though the latter may include a grace period.
The Russell 2000 led the charge, rising 0.7% to 2,244, as small-cap stocks continued to rebound. 
The Nasdaq 100 gained 0.5%, climbing to 22,815, supported by strength in megacap tech names. Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) grabbed headlines once again, with its market capitalization hitting $4 trillion, solidifying its lead as the world's most valuable company. According to the <a href="https://www.ft.com/content/e496f80f-1789-46b3-9275-a3f54344047e">Financial Times</a>, Nvidia is planning to launch a new AI chip designed specifically for China as soon as September. 
The S&amp;P 500 added 0.4%, trading at 6,250, while the Dow Jones Industrial Average inched 0.3% higher. 
Sector performance was mixed, with utilities outperforming while consumer staples lagged.
In the bond market, Treasury yields fell 5 basis points ahead of a key 10-year auction later in the day. The U.S. dollar index held steady, ahead of the Federal Reserve's minutes from the June FOMC meeting, released on Wednesday afternoon.
Oil prices climbed for a third consecutive session, rising to $69 per barrel, while gold held flat at $3,325. In crypto, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) advanced 0.9% to $109,235, trading just 2.5% below its all-time highs set in May.
<h2 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day %</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,244.10</td>
<td>0.7%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>22,815.57</td>
<td>0.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,250.79</td>
<td>0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,388.59</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 1:20 p.m. ET </figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) rose 0.4% to $572.28.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.3% higher to $443.81.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.4% to $554.81.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.7% to $222.70.</li>
<li>The&nbsp;Utilities&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 0.8%; the&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 1%.</li>
</ul>
<h2 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h2>
<ul class="wp-block-list">
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) climbed nearly 5% after delivering 60 aircraft in June, a 27% increase from a year ago. The monthly total included sales to Chinese customers, appearing for the first time in months—a potential sign of recovery for the planemaker.</li>
<li>AES Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) jumped 17% following a Bloomberg report that the renewable energy company is considering strategic alternatives, including a potential sale, as large investment firms express interest in a takeover.</li>
<li>Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) soared 21% to $104.80 after Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) announced a $10 billion deal to acquire the biotech firm, which specializes in treatments for lung diseases.</li>
</ul>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46314139/polymarket-bettors-see-50-chance-of-fed-september-rate-cuts-as-trump-turns-up-heat-on-powell">Polymarket Bettors See 50% Chance Of Fed September Rate Cuts As Trump Turns Up Heat On Powell </a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

Economics

Federal Reserve

Tech

ETFs

$BTC

VRNA

Nvidia's $4 Trillion Milestone Lifts Wall Street: What's Moving Markets Wednesday?

Looking into the current session, Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) shares are trading at $82.37, after a 1.23% increase. Moreover, over the past month, the stock increased by 4.43%, but in the past year, fell by 34.97%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1752084047_0.png" alt="Past Year Chart" />

<h3>Merck &amp; Co P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 29.42 in the Pharmaceuticals industry, Merck &amp; Co Inc. has a lower P/E ratio of 11.83. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1752084047_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Merck & Co

WIIM

Merck shares are trading higher after the company announced it will acquire Verona Pharma.

Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) agreed on Wednesday to acquire Verona Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents eight ordinary shares of Verona Pharma.
Through the acquisition of this <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">respiratory disease-focused</a> company, Merck will add Ohtuvayre (ensifentrine), a first-in-class, selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its cardiovascular and pulmonary pipeline and portfolio.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45692578/regeneron-sanofi-stock-falls-after-uneven-smokers-lung-drug-data" rel="noreferrer noopener">Regeneron, Sanofi Stock Falls After Uneven Smoker&#8217;s Lung Drug Data</a>
The U.S. Food and Drug Administration approved Ohtuvayre in June 2024 for the maintenance treatment of chronic obstructive pulmonary <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39526177/first-inhaled-copd-therapy-in-over-2-decades-fda-approves-verona-pharmas-first-commercial-product" rel="noreferrer noopener">disease (COPD) in adult patients</a>.
Ohtuvayre is the first novel inhaled mechanism for COPD in more than 20 years, combining bronchodilator and non-steroidal anti-inflammatory effects.
Ohtuvayre is also being evaluated in clinical trials for non-cystic fibrosis bronchiectasis.
The transaction is expected to close in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46314549/merck-to-acquire-verona-pharma-expanding-its-portfolio-to-include-ohtuvayre-ensifentrine-a-first-i" rel="noreferrer noopener">fourth quarter of 2025</a> and will result in the capitalization of most of the purchase price as an intangible asset for Ohtuvayre.
The Financial Times, which <a href="https://www.ft.com/content/bf1c2253-15b3-426a-975d-15ddca1d84a5" target="_blank" rel="noreferrer noopener">first</a> reported the possible takeover, added that the deal would be Merck's biggest since it bought Prometheus Biosciences <a href="https://www.benzinga.com/markets/equities/23/04/31825415/merck-acquires-prometheus-biosciences-for-10-8b-strengthening-its-immunology-pipeline" target="_blank" rel="noreferrer noopener">for $10.8 billion in 2023</a>.
It reflects a growing trend of big drug companies acquiring biotech firms that already have approved, revenue-generating products, as they seek to replace revenue from major drugs losing patent protection.
The FT report states that Merck's cancer treatment Keytruda, the world's top-selling drug with nearly $30 billion in annual revenue, is set to come off patent and face U.S. government price-setting rules as early as 2028.
Since Rob Davis became Merck's CEO in April 2021, the company has been one of the most active in the pharmaceutical industry in terms of acquisitions and licensing, with the highest deal count and spending. However, investors have been pushing for even more deals in recent months to help offset the expected decline in sales once Keytruda loses patent protection.
The FT report highlighted that Davis was seeking deals worth between $1 billion and $15 billion, or even more, if the opportunity was right.
Earlier this year, Merck signed a licensing agreement worth up to $2.2 billion with China&#8217;s Jiangsu Hengrui Pharmaceuticals for the global rights <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44477157/merck-partners-with-hengrui-pharma-in-177-billion-deal-for-cardiovascular-treatment" rel="noreferrer noopener">to a heart disease drug</a>.
According to a July media report, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) was reportedly in talks with Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) about a partnership worth <a target="_blank" href="https://www.benzinga.com/news/contracts/25/07/46249640/astrazeneca-in-15b-talks-for-drug-that-could-upend-lung-cancer-treatment" rel="noreferrer noopener">up to $15 billion.</a>
Price Action: VRNA stock rose 20.7% to $104.83. MRK stock was up 0.50% at $81.78 during the premarket session at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46314112/super-micro-accelerates-european-footprint-to-meet-exploding-ai-needs" target="_blank" rel="noreferrer noopener">Super Micro Accelerates European Footprint To Meet Exploding AI Needs</a></li>
</ul>
Photo: Shutterstock

Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug

Acquisition aligns with Merck's science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Merck to hold investor call at 8 a.m. ET today
Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, and Verona Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.
Through this acquisition Merck will add Ohtuvayre&#xAE; (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its growing cardio-pulmonary pipeline and portfolio. The U.S. Food and Drug Administration <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.veronapharma.com%2Fnews%2Fverona-pharma-announces-us-fda-approval-of-ohtuvayre-ensifentrine%2F&amp;esheet=54287806&amp;newsitemid=20250708346048&amp;lan=en-US&amp;anchor=approved&amp;index=1&amp;md5=aa256e353e68095e072f61ca5f9dd864">approved</a> Ohtuvayre in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first novel inhaled mechanism for the treatment of COPD in more than 20 years and combines bronchodilator and non-steroidal anti-inflammatory effects. Ohtuvayre is also being evaluated in clinical trials for the treatment of non-cystic fibrosis bronchiectasis.
The transaction was unanimously approved by both the Merck and Verona Pharma Boards of Directors and is intended to be effected by way of a scheme of arrangement under UK law. Closing of the proposed acquisition is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act, approval of Verona Pharma shareholders, sanction by the High Court of Justice of England and Wales and other customary conditions. The transaction is expected to close in the fourth quarter of 2025 and will result in the capitalization of most of the purchase price as an intangible asset for Ohtuvayre (which will be amortized as a GAAP-only charge over the life of the product). &nbsp;

Merck To Acquire Verona Pharma In $10B Deal, Offering $107 Per ADS

<a href="https://www.ft.com/content/bf1c2253-15b3-426a-975d-15ddca1d84a5" title="https://www.ft.com/content/bf1c2253-15b3-426a-975d-15ddca1d84a5">https://www.ft.com/content/bf1c2253-15b3-426a-975d-15ddca1d84a5</a>
<a href="https://www.ft.com/content/bf1c2253-15b3-426a-975d-15ddca1d84a5" title="https://www.ft.com/content/bf1c2253-15b3-426a-975d-15ddca1d84a5">https://www.ft.com/content/bf1c2253-15b3-426a-975d-15ddca1d84a5</a>

Financial Times Reported Earlier, Merck Near Deal To Acquire Verona For ~$107 Per American Depository Share

Press Releases

FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial

Small Cap

Opinion

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

Legal

MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

CGON

CLDI

RHHBF

VRTX

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Eli Lilly

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Morgan Stanley

Citigroup

Cantor Fitzgerald

Guggenheim

Deutsche Bank

Screenshot 2025-07-10 at 8.34.03 PM

KERX

When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern.

SeaStar Medical&#39;s QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka

Screenshot 2025-05-21 at 5.43.26 PM

SPACE

Emerging Markets

ASTI

Space Exploration Will Continue Despite NASA Budget Cuts – How Will CIGS-Maker Ascent Solar (ASTI) Be Impacted?

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Comments

Merck & Co

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL